Antibe Therapeutics Inc

Receive alerts
Market Cap:
$102.69 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-16 of 16


Antibe Therapeutics sees fiscal first quarter revenue rise thanks to higher sales in the United States

For the three months ended June 30, the company said revenue from product sales increased to C$2.763 million, up from C$2.543 million a year earlier...

3 weeks, 4 days ago

Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain ‘proceeding well’

A total of 360 patients with osteoarthritis of the knee are being randomized to either placebo or one of three doses of ATB-346 administered once daily...

3 weeks, 5 days ago

Antibe Therapeutics to sell units to raise money to further develop lead osteoarthritis drug

Antibe is working on getting the drug ready for an investigational new drug (IND) application, as well as a meeting with the Food and Drug Administration...

on 07/23/2019

Antibe Therapeutics hosts successful annual and special general meeting

The firm said shareholders elected six directors at its annual general meeting...

on 07/02/2019

Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track...

on 06/25/2019

Antibe Therapeutics CEO Dan Legault on why the multibillion-dollar NSAID market needs disruption

The Toronto-based biotech company is aiming to build a new generation of NSAIDs to compete against the Bayers and Pfizers of the world...

on 06/07/2019

Antibe Therapeutics targets US$9 billion market with second pipeline drug ATB-352 for severe pain

The Toronto-based company is targeting the postoperative pain sector with ATB-352, a potent and non-addictive drug for the treatment of severe pain...

on 06/03/2019

Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology

A new research article in the British Journal of Pharmacology highlights the success of Antibe's 2B GI safety trial for its lead pain treatment ATB-346...

on 04/16/2019

Antibe Therapeutics is poised to disrupt the global pain management industry

The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use...

on 04/12/2019

Antibe grants Kinght commercial rights for drug candidates

The deal covers Antibe's anti-inflammatory and pain drugs in Canada, Israel, Romania, Russia and sub-Saharan Africa....

on 11/16/2015

Antibe Therapeutics seeks to fill market void with “ground-breaking” class of painkiller drugs

Antibe Therapeutics is seeking to fill a vast market void with a “ground-breaking” class of painkiller drugs.  While the journey bringing the drug to market may be long and arduous, the end result appears to be well worth the toil, says president and CEO, Dan Legault. ...

on 10/09/2013